Volatile Organic Compounds in Exhaled Air and Sweat of Patients Treated by Immunotherapy for Lung Cancer: Research on Biomarkers for Early Therapeutic Response (Immuno-VOC)

Volatile Organic Compounds in Exhaled Air and Sweat of Patients Treated by Immunotherapy for Lung Cancer: Research on Biomarkers for Early Therapeutic Response

Volatile Organic Compounds in Exhaled Air and Sweat of Patients Treated by Immunotherapy for Lung Cancer: Research on Biomarkers for Early Therapeutic Response

The study of volatile organic compounds (VOC) detected in exhaled air or in sweat, is an innovative research area for respiratory diseases. The volatolomic analysis can be done either by the technique of the mass spectrometry which allows the identification of each VOC in the exhaled air or by the technique of electronic nose, simpler and faster, which provides an idea of the general profile of the VOC without identifying them. The VOC have shown their interest in some situations, such as diagnostic or prognostic tool in patients followed for thoracic tumorous pathology or bronchial or pulmonary vascular diseases. Immunotherapy is a new therapeutic approach used in non small cell lung cancer in a late stage. VOC analysis could allow to identify biomarkers of early response to immunotherapy. The study of VOC could help in the optimisation of immunotherapy prescription in lung cancer.

Comparison of variation of Volatil Organic Compound (VOC) profiles in exhaled air of patients before and during immunotherapy

Correlation of variation with response to immunotherapy at week 9, 18 and 27 (according to RECIST criteria)

Comparison of variation of Volatil Organic Compound (VOC) profiles in sweat of patients before and during immunotherapy

Correlation of variation with response to immunotherapy at week 9, 18 and 27 (according to RECIST criteria)

Correlation between Volatil Organic Compound (VOC) profile before treatment and radiological response at 9, 18 and 27 weeks (defined by RECIST criteria)

Correlation between variation of Volatil Organic Compound (VOC) profiles and apparition of drug toxicity at 9, 18 and 27 weeks

Comparison of performance of Volatil Organic Compound (VOC) from exhaled air versus Volatil Organic Compound (VOC) from sweat

Comparison of performance of Volatil Organic Compound (VOC) from mass spectrometry versus Volatil Organic Compound (VOC) from electronic noses

Inclusion Criteria: patient aged > 18 years old patient with metastatic non-small cell lung cancer with marketing authorisation criteria for immunotherapy preserved overall condition (Performans Status 1) signed informed consent patient with healthcare insurance Non Inclusion Criteria: patient with oxygen therapy or invasive ventilation patient unable to perform a slow vital capacity systemic corticosteroid therapy more than 10 mg per day of prednisone equivalent previous treatment with immunotherapy dermatological therapy interfering with sweat collection (psoriasis, irritant dermatitis, for instance) Patient deprived of liberty by judicial or administrative decision